GL1X · GenesisL1 explorer

Research workbench

Covalent GTP-competitive inhibitors of KRAS G12C: guanosine bisphosphonate analogs

Analyse Covalent GTP-competitive inhibitors of KRAS G12C: guanosine bisphosphonate… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5KYK
Type
protein
Length
483 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
GTPase KRAS
UniProt
P01116
Ligands
6ZD
Pockets
7 · best druggability 0.79

Structure

x-ray diffraction · 3 distinct chains · 36% helix, 25% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AGTPase KRASprotein15937% helix, 26% strandP01116
BGTPase KRASprotein16036% helix, 26% strandP01116
CGTPase KRASprotein16435% helix, 25% strandP01116

Ligands and binding sites

  • 6ZD · 5'-O-[(R)-[({2-[(chloroacetyl)amino]ethyl}sulfamoyl) methyl](hydroxy)phosphoryl]guanosine · ligand · 3 copies · chains A, B, C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111100.790.81112empty
21330.510.8019empty
31260.470.7818empty
42180.470.7425empty
51100.410.77266ZD

Interfaces

3 interfaces between chains.

  • A–B · 344 Ų buried · 5 hydrogen bonds · protein-protein
  • A–C · 331 Ų buried · 5 hydrogen bonds · protein-protein
  • B–C · 330 Ų buried · 5 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 9 covalent (covalent ligand).

Compared structures

  • 5KYK · Covalent GTP-competitive inhibitors of KRAS G12C: Guanosine bisphosphonate Analogs · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.